CG
BCRX icon

Cutler Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cutler Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,900
Closed -$1K – 4385
2022
Q3 		$1K Sell
5,900
-2,700
-31% -$34.7K ﹤0.01% 4425
2022
Q2 		$1K Sell
8,600
-21,000
-71% -$217K ﹤0.01% 4501
2022
Q1 		$15K Buy
29,600
+16,800
+131% +$269K ﹤0.01% 3267
2021
Q4 		$6K Sell
12,800
-600
-4% -$7.94K ﹤0.01% 4031
2021
Q3 		$7K Buy
13,400
+1,500
+13% +$23.7K ﹤0.01% 4188
2021
Q2 		$5K Buy
+11,900
New +$162K ﹤0.01% 4396
2020
Q3 		– Sell
-15,100
Closed -$13K – 4665
2020
Q2 		$13K Buy
+15,100
New +$60.3K ﹤0.01% 2666
2019
Q2 		– Sell
-2,000
Closed -$5K – 4212
2019
Q1 		$5K Sell
2,000
-9,000
-82% -$77.1K ﹤0.01% 2878
2018
Q4 		$9K Buy
11,000
+3,900
+55% +$30.3K ﹤0.01% 2573
2018
Q3 		$6K Buy
+7,100
New +$47.7K ﹤0.01% 2921
2017
Q4 		– Sell
-11,000
Closed -$4K – 4897
2017
Q3 		$4K Sell
11,000
-198,100
-95% -$1.01M ﹤0.01% 4515
2017
Q2 		$97K Buy
209,100
+99,100
+90% +$604K ﹤0.01% 1878
2017
Q1 		$22K Sell
110,000
-2,900
-3% -$20.2K ﹤0.01% 3224
2016
Q4 		$141K Buy
112,900
+55,500
+97% +$289K 0.01% 1593
2016
Q3 		$16K Buy
57,400
+7,400
+15% +$29.6K ﹤0.01% 3635
2016
Q2 		$4K Hold
50,000
– – ﹤0.01% 5076
2016
Q1 		$5K Sell
50,000
-31,200
-38% -$138K ﹤0.01% 4791
2015
Q4 		$42K Buy
+81,200
New +$807K ﹤0.01% 2638

Other funds holding BCRX

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Cutler Group's BCRX Position: Q3 2022 in Review

Cutler Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 1,443 shares — an estimated $18.6K sold.

Cutler Group first reported a position in BCRX in Q4 2015 and held it in 20 quarters. The position peaked at $331K in Q3 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Cutler Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 1,443 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $18.6K.
  • Cutler Group first reported a position in BioCryst Pharmaceuticals in Q4 2015 and held it in 20 quarters.
  • Cutler Group's BioCryst Pharmaceuticals position peaked at $331K in Q3 2021.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.